ReviewCurrent oncology reports2010
CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance.
Review in Current oncology reports, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.
- Genetic Variation and Hot Flashes: A Systematic Review.The Journal of clinical endocrinology and metabolism · 2020Pooled it
- Comparison of the Efficacy and Safety of Pregabalin and Duloxetine in Taxane-Induced Sensory Neuropathy: A Randomized Controlled Trial.Clinical drug investigation · 2020Trial
- Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial.British journal of cancer · 2012Trial
- Functionalized liposomes for targeted breast cancer drug delivery.Bioactive materials · 2023Review
- Cell cycle related long non-coding RNAs as the critical regulators of breast cancer progression and metastasis.Biological research · 2023Review
- Review
- Hepatic Models in Precision Medicine: An African Perspective on Pharmacovigilance.Frontiers in genetics · 2022Article
- Article
- Silencing of syndecan-binding protein enhances the inhibitory effect of tamoxifen and increases cellular sensitivity to estrogen.Cancer biology & medicine · 2018Article
- Pharmacogenomics Guided-Personalization of Warfarin and Tamoxifen.Journal of personalized medicine · 2017Review
- Tumoral expression of drug and xenobiotic metabolizing enzymes in breast cancer patients of different ethnicities with implications to personalized medicine.Scientific reports · 2017Article
- PTS: a pharmaceutical target seeker.Database : the journal of biological databases and curation · 2017Article
- Prediction of tamoxifen outcome by genetic variation of CYP2D6 in post-menopausal women with early breast cancer.British journal of clinical pharmacology · 2014Article
- Tamoxifen for women at high risk of breast cancer.Breast cancer (Dove Medical Press) · 2014Review
- Effects of CYP2D6 and UGT2B7 polymorphisms on pharmacokinetics of tamoxifen in Thai breast cancer patients.Breast cancer (Dove Medical Press) · 2013Article
- Trends in co-prescribing of antidepressants and tamoxifen among women with breast cancer, 2004-2010.Breast cancer research and treatment · 2013Article
- Hormonal therapy in breast cancer: a model disease for the personalization of cancer care.Molecular oncology · 2012Review
- Germline pharmacogenomics in oncology: decoding the patient for targeting therapy.Molecular oncology · 2012Review
- Breast cancer medications and vision: effects of treatments for early-stage disease.Current eye research · 2011Review
- The use of genomic information to optimize cancer chemotherapy.Seminars in oncology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The selective estrogen receptor modulator tamoxifen has been used for more than three decades to treat metastatic and early-stage receptor-positive breast cancer and, more recently, to prevent the disease. Biotransformation of tamoxifen to the potent antiestrogen endoxifen is performed by cytochrome P450 (CYP) enzymes, in particular the CYP2D6 isoform. Genetic variants in the CYP2D6 gene may result in CYP2D6 enzymes with reduced or null activity. Strong and intermediate inhibitors of CYP2D6, which may be used to treat hot flashes or psychiatric conditions in breast cancer patients, can also negatively impact enzyme function. Prospective data are lacking, but the balance of current evidence strongly suggests that, compared with women with two wild-type alleles, the presence of two null alleles, and possibly one null allele, predicts reduced tamoxifen metabolism and an inferior outcome in postmenopausal women with early breast cancer who receive adjuvant treatment with the drug. Unfortunately, studies to date have been largely retrospective and the interpretation of their results is limited by examination of archival tissue samples and the inclusion of heterogeneous populations. Although we do not currently recommend routine CYP2D6 testing for women who do not have alternative standard therapies, the use of concomitant strong or intermediate inhibitors of CYP2D6 should be avoided if feasible. This review summarizes the literature to date with a focus on clinically relevant recent studies that examined the association between CYP2D6 polymorphisms and tamoxifen-associated outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.